Zenas BioPharma (ZBIO) Non Operating Income (2023 - 2026)

Zenas BioPharma's Non Operating Income history runs 4 years deep, the most recent figure standing at -$3.6 million for Q1 2026.

• On a quarterly basis, Non Operating Income fell 202.39% year-over-year to -$3.6 million in Q1 2026; TTM through Mar 2026 was -$1.9 million, a 117.54% decrease from a year earlier, with the FY2025 full-year figure at $5.2 million, down 28.49% from the prior year.
• Non Operating Income eased to -$3.6 million in Q1 2026 per ZBIO's latest filing, from -$2.4 million in the prior quarter.
• Across five years, Non Operating Income topped out at $3.6 million in Q1 2025 and bottomed at -$3.6 million in Q1 2026.
• The 4-year median for Non Operating Income is $1.1 million (2025), against an average of $855454.5.
• Across the five-year window, Non Operating Income soared 14962.5% in 2024 and slumped 202.39% in 2026, its largest moves.
• Year by year, Non Operating Income stood at $493000.0 in 2023, then surged by 599.39% to $3.4 million in 2024, then tumbled by 168.21% to -$2.4 million in 2025, then plunged by 54.63% to -$3.6 million in 2026.
• Per Business Quant, the three latest ZBIO Non Operating Income figures stand at -$3.6 million (Q1 2026), -$2.4 million (Q4 2025), and $1.1 million (Q3 2025).